Which antihypertensive treatment is better for mild to moderate hypertension in pregnancy?

BMJ. 2022 Jan 18:376:e066333. doi: 10.1136/bmj-2021-066333.

Authors

Danielle Ashworth¹, Cheryl Battersby², Marcus Green³, Pollyanna Hardy⁴, Richard J McManus⁵, Catherine Cluver⁶, Lucy C Chappell⁷

Affiliations

¹ King's College London, UK.
² Imperial College London, UK.
³ Action on Pre-eclampsia (APEC), Evesham WR11 4EU, UK.
⁴ National Perinatal Epidemiology Unit Clinical Trials Unit, University of Oxford, UK.
⁵ University of Oxford, UK.
⁶ Department of Obstetrics and Gynaecology, Stellenbosch University, Cape Town, South Africa.
⁷ King's College London, UK lucy.chappell@kcl.ac.uk.

PMID: 35042721
DOI: 10.1136/bmj-2021-066333

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Antihypertensive Agents / therapeutic use*
Female
Humans
Hypertension, Pregnancy-Induced / drug therapy*
Labetalol / therapeutic use
Methyldopa / therapeutic use
Nifedipine / therapeutic use
Pregnancy
Prenatal Care / methods
Prenatal Care / standards*
Treatment Outcome

Substances

Antihypertensive Agents
Methyldopa
Nifedipine
Labetalol